Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain.
‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director .
The principle study that guarantees its effectiveness is the MOVES clinical trial , published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondroitin sulphate and glucosamine has an effectiveness comparable to the anti-inflammatory drug celecoxib after six months of treatment in patients with osteoarthritis and moderate to severe pain. It was observed that the combination of these two drugs relieves pain in a clinically relevant way. It also improves functional capacity, stiffness, relieves inflammation and joint effusion.
With these new approvals, a total of six European countries have approved Bioiberica brand’s combination of chondroitin sulphate and glucosamine hydrochloride. This year, the company plans to sign licensing and distribution agreements with companies specialised in the osteoarticular field to launch the product in the five countries where the drug was recently approved.
Bioiberica is the first European producer of chondroitin sulfate and international leader in joint health and chondroprotection thanks to a constant dedication and commitment to science and research. Vertically integrated, from the active ingredient to the finished product, Bioiberica offers its customers all their medical, scientific and commercial knowledge for the joint development of the market.
Alba Soler i Conangla, +34 93 490 49 08
PR- Corporate Communications Director
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-PSMF/OPEN-SHARING27.6.2019 14:02:08 CEST | Pressemeddelelse
U.S. Food and Drug Administration Supports Principles of Open Sharing of Data
CA-MOBILEIRON27.6.2019 14:02:08 CEST | Pressemeddelelse
MobileIron Research Reveals 8 in 10 IT Leaders Want to Eliminate Passwords and Expect Mobile Devices to Become Primary Authentication to the Enterprise
NY-TMD-SECURITY27.6.2019 13:02:14 CEST | Pressemeddelelse
TMD Security Announces Global Agreement to Integrate Easthouse’s Key-less Locks for ATM Top Box and Safe into its TMD Access Management Solution
NY-MOODYS/-TEAM827.6.2019 13:02:14 CEST | Pressemeddelelse
Moody’s and Team8 Launch Joint Venture to Create a Global Cyber Risk Standard
GSMA27.6.2019 13:02:13 CEST | Pressemeddelelse
GSMA Announces Winners of 2019 Asia Mobile Awards
NTT-COM/E-SHELTER27.6.2019 12:02:17 CEST | Pressemeddelelse
e-shelter Opens Fourth Data Center Campus in Frankfurt
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum